PODD:NGS-Insulet Corporation (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 326.64

Change

+5.28 (+1.64)%

Market Cap

USD 2.13B

Volume

0.70M

Analyst Target

USD 241.41
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insulet Corp is a medical device company that develops, manufactures and sells OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.82 (+0.97%)

USD 33.20B
MASI Masimo Corporation

+7.12 (+4.74%)

USD 8.49B
BRKR Bruker Corporation

+1.65 (+4.65%)

USD 5.69B
TMDX TransMedics Group Inc

+4.28 (+3.44%)

USD 4.11B
IRTC iRhythm Technologies Inc

+3.68 (+2.58%)

USD 3.38B
PRCT Procept Biorobotics Corp

+1.15 (+2.00%)

USD 3.17B
LIVN LivaNova PLC

+2.14 (+5.11%)

USD 2.40B
SSII SS Innovations International I..

-1.74 (-19.73%)

USD 2.20B
NVCR Novocure Ltd

+0.64 (+3.45%)

USD 1.94B
QDEL Quidel Corporation

+1.52 (+5.11%)

USD 1.89B

ETFs Containing PODD

EDOC:AU 8.02 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 5.71 % 0.00 %

-1,373.55 (2.48%)

USD 4.76M
GDOC Goldman Sachs ETF Trust 5.07 % 0.00 %

+0.39 (+2.48%)

USD 0.02B
EKG First Trust Nasdaq Lux Di.. 4.98 % 0.00 %

+0.43 (+2.48%)

USD 3.28M
EDOC Global X Telemedicine & D.. 4.96 % 0.00 %

N/A

USD 0.04B
EDOC:SW Global X Telemedicine & D.. 4.91 % 0.00 %

+0.14 (+2.48%)

N/A
CIB0:XETRA VanEck Bionic Engineering.. 4.85 % 0.00 %

+0.26 (+2.48%)

N/A
DDOC:F Global X Telemedicine & D.. 4.51 % 0.00 %

+0.20 (+2.48%)

N/A
EDOC:LSE Global X Telemedicine & D.. 4.43 % 0.00 %

+0.19 (+2.48%)

USD 4.27M
EDOG:LSE Global X Telemedicine & D.. 4.43 % 0.00 %

+0.13 (+2.48%)

USD 0.30M
FDOC:LSE 4.22 % 0.00 %

N/A

N/A
FDHT:XETRA 4.04 % 0.00 %

N/A

N/A
FDHT Fidelity Covington Trust .. 3.94 % 0.00 %

+0.30 (+2.48%)

USD 8.09M
CYBG:LSE VanEck Bionic Engineering.. 3.90 % 0.00 %

+0.32 (+2.48%)

N/A
CURE:XETRA VanEck Genomics and Healt.. 3.57 % 0.00 %

+0.21 (+2.48%)

N/A
RJMG First Trust Exchange-Trad.. 2.95 % 0.00 %

+0.42 (+2.48%)

USD 0.01B
BMED BlackRock Future Health E.. 2.81 % 0.00 %

+0.26 (+2.48%)

USD 2.84M
2B78:XETRA iShares Healthcare Innova.. 2.76 % 0.00 %

+0.05 (+2.48%)

USD 1.05B
FXH First Trust Health Care A.. 2.74 % 0.63 %

+2.08 (+2.48%)

USD 0.90B
HLTH:AU VanEck Global Healthcare .. 2.50 % 0.00 %

+0.11 (+2.48%)

USD 0.06B
XHE SPDR® S&P Health Care Eq.. 2.29 % 0.35 %

+2.32 (+2.48%)

USD 0.17B
FHH:CA First Trust AlphaDEX US H.. 2.16 % 0.77 %

+0.94 (+2.48%)

CAD 0.01B
HEAL:SW iShares Healthcare Innova.. 2.13 % 0.00 %

+0.02 (+2.48%)

USD 1.05B
QQQJ Invesco NASDAQ Next Gen 1.. 1.44 % 0.00 %

+0.51 (+2.48%)

USD 0.60B
FSCS First Trust SMID Capital .. 1.20 % 0.00 %

+0.87 (+2.48%)

USD 0.04B
JOET Virtus ETF Trust II 0.91 % 0.00 %

+0.69 (+2.48%)

USD 0.19B
RNMC 0.00 % 0.60 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+8.63 (+2.48%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.12 (+2.48%)

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.03 (2.48%)

N/A
BKMC BNY Mellon US Mid Cap Cor.. 0.00 % 0.00 %

+1.90 (+2.48%)

USD 0.34B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

+0.12 (+2.48%)

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

+0.12 (+2.48%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.12% 83% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.12% 83% B 88% B+
Trailing 12 Months  
Capital Gain 83.69% 92% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.69% 92% A 92% A
Trailing 5 Years  
Capital Gain 76.96% 85% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.96% 85% B 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 5.48% 57% F 59% D-
Dividend Return 5.48% 57% F 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.40% 76% C+ 53% F
Risk Adjusted Return 16.40% 74% C 53% F
Market Capitalization 2.13B 99% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 53.66 25% 19%
Price/Book Ratio 16.43 10% 8%
Price / Cash Flow Ratio 50.80 6% 5%
Price/Free Cash Flow Ratio 53.25 4% 7%
Management Effectiveness  
Return on Equity 43.03% 100% 96%
Return on Invested Capital 17.97% 87% 85%
Return on Assets 6.80% 96% 89%
Debt to Equity Ratio 106.97% 35% 20%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.